Australia markets open in 7 hours 48 minutes

Lumos Pharma, Inc. (LUMO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.27-0.03 (-0.35%)
As of 11:06AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close9.30
Open9.33
Bid9.24 x 800
Ask9.45 x 1000
Day's range9.25 - 9.45
52-week range7.23 - 36.72
Volume1,951
Avg. volume62,612
Market cap77.452M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.16
Earnings date08 Nov 2021 - 12 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.00
  • GlobeNewswire

    Lumos Pharma to Participate in September Investor Conferences

    AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September. Event:H.C. Wainwright 23rd Annual Global Investor Conference – September 13-15Presentation:Pre-recorded presentation available beginning September 13 at 7:0

  • Simply Wall St.

    Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year

    When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

  • GlobeNewswire

    Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

    • Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progress AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ending June